Revance Therapeutics Long Term Debt

Revance Therapeutics posts a long-term debt of $490M as of September 2024. That compares with $470M in the prior-year period — up 4.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Revance Therapeutics's long-term debt was $470M. The latest reading is $490M — a 4.6% year-over-year increase (period ending September 2024). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Revance Therapeutics's financial statement story. At $490M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for RVNC's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Revance Therapeutics's other metric pages and overview cover the third.

Judging Revance Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $490M here, then scan peer and history charts to see if the gap is persistent.